Prolactin binding by human mammary carcinoma: Relationship to estrogen receptor protein concentration and patient age Barbara Rae-VenterTakuma NemotoThomas L. Dao Reports Pages: 233 - 243
The prophylaxis of rat and mouse mammary gland tumorigenesis by suppression of prolactin secretion: A reappraisal Clifford W. WelschMargaret Goodrich-SmithLeslie Roth Reports Pages: 225 - 232
Estradiol stimulates synthesis of a major intracellular protein in a human breast cancer cell line (MCF-7) Dean P. EdwardsDavid J. AdamsWilliam L. McGuire Reports Pages: 209 - 223
Karyotype analysis of a human mammary sarcoma explant in vitro T. R. ChenG. Seman Reports Pages: 203 - 208
Suppression of estrogens with Aminoglutethimide and hydrocortisone (medical adrenalectomy) as treatment of advanced breast carcinoma: A review R. J. Santen Review Pages: 183 - 202
Potential and problems with growth of breast cancer in a human tumor cloning system Daniel D. Von HoffJohn Sandbachthe South Central Texas Human Tumor Cloning Group US-Japan Conference on Chemoendocrine Therapy Pages: 141 - 148
Hormone receptors and obesity in Japanese women with breast cancer Keijiro KunoAtsuo FukamiFujio Kasumi US-Japan Conference on Chemoendocrine Therapy Pages: 135 - 139
Adjuvant therapy for stage II, estrogen receptor negative breast cancer William A. Knight IIIGary M. ClarkWilliam L. McGuire US-Japan Conference on Chemoendocrine Therapy Pages: 131 - 134
Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer Masaru IzuoYuichi IinoKeiichi Endo US-Japan Conference on Chemoendocrine Therapy Pages: 125 - 130
Combined chemo-hormonal therapy in breast cancer: A hypothesis C. Kent Osborne US-Japan Conference on Chemoendocrine Therapy Pages: 121 - 123
A prospective evaluation of chemohormonal therapy remission maintenance in advanced breast cancer Douglass C. TormeyRebecca GelmanGeoffrey Falkson US-Japan Conference on Chemoendocrine Therapy Pages: 111 - 119
Chemoendocrine therapy in advanced breast cancer David T. KiangB. J. Kennedy US-Japan Conference on Chemoendocrine Therapy Pages: 105 - 109
Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival Andrea ManniOlof H. PearsonBahauddin M. Arafah US-Japan Conference on Chemoendocrine Therapy Pages: 97 - 103
Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment Robin M. L. MurrayPaula Pitt Report Pages: 91 - 95
Adjuvant therapy of stage II breast cancer Charles A. HubayOlof H. Pearson27 Participating Investigators US-Japan Conference on Chemoendocrine Therapy Pages: 77 - 82
Adjuvant chemo-endocrine therapy for androgen-dependent mammary tumor in mice Naomi UchidaKenji YamaguchiKeishi Matsumoto US-Japan Conference on Chemoendocrine Therapy Pages: 69 - 75
Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer John H. GlickRichard H. CreechMichael Varano US-Japan Conference on Chemoendocrine Therapy Pages: 59 - 68
Tamoxifen alone versus tamoxifen plus 1-(2-tetrahydrofuryl)-5-fluorouracil in the treatment of advanced breast cancer: A sequential trial Tomio WadaHiroki KoyamaToshio Terasawa US-Japan Conference on Chemoendocrine Therapy Pages: 53 - 58
The interpretation of trials: Combined hormonal therapy and chemotherapy in disseminated breast cancer Stephen K. Carter US-Japan Conference on Chemoendocrine Therapy Pages: 43 - 51
Correlation of primary breast cancer histopathology and estrogen receptor content Edwin R. FisherC. Kent OsborneHouston C. Ford Reports Pages: 37 - 41
Estrogen receptor measurement in low-protein breast cancer cytosols Bernard L. PowellMinerva De La GarzaWilliam L. McGuire Viewpoints Pages: 33 - 35
A commentary on the role of the surgeon in primary breast cancer Bernard Fisher Viewpoints Pages: 17 - 26
The surgeon's role in breast cancer: Changing concepts Henry Patrick Leis Jr. Viewpoints Pages: 5 - 15
